A 38-year-old man from Mumbai presents with a 3-year history of progressive nasal obstruction and recurrent sinusitis. On anterior rhinoscopy, multiple pale, smooth, glistening masses are seen bilaterally in the nasal cavity. CT paranasal sinuses shows opacification of the maxillary and ethmoid sinuses with polypoid masses. Serum IgE is markedly elevated at 2500 IU/mL. He reports a lifelong history of asthma and eczema. What is the most likely diagnosis?

Explanation

## Clinical Diagnosis: Allergic Rhinitis with Nasal Polyps Secondary to Atopy ### Key Clinical Features **Key Point:** The combination of bilateral pale smooth glistening polyps, markedly elevated serum IgE (2500 IU/mL), lifelong atopy (asthma + eczema), and bilateral maxillary/ethmoid sinus opacification is most consistent with allergic rhinitis with nasal polyposis secondary to atopy — NOT allergic fungal sinusitis (AFS). ### Why NOT Allergic Fungal Sinusitis (AFS)? AFS is a common distractor here. While AFS does feature elevated IgE and atopy, it has **specific distinguishing features absent in this case**: - **AFS hallmarks**: Thick, inspissated "peanut butter-like" fungal mucin on CT (heterogeneous hyperdense material), often **unilateral or asymmetric** involvement, positive fungal culture/stain (Bipolaris, Aspergillus), and characteristic CT finding of **central hyperdensity** within sinus opacification (due to fungal concretions and heavy metals) - **This patient**: Bilateral symmetric polypoid masses with homogeneous opacification — no mention of heterogeneous CT density, no fungal culture, no thick inspissated mucin - The stem describes **polypoid masses** (not fungal mucin), and the clinical picture is dominated by **atopy** (asthma + eczema since childhood), which is the primary driver ### Pathophysiology of Atopic Nasal Polyps 1. **Atopic Predisposition** — Th2-mediated immune response with IgE sensitization to environmental allergens 2. **Chronic Allergic Inflammation** — Eosinophilic infiltration of nasal mucosa, IL-4/IL-13 driven 3. **Polyp Formation** — Submucosal edema and mucosal hypertrophy over years → pale, smooth, glistening masses 4. **Secondary Sinusitis** — Obstruction of ostiomeatal complex → bacterial colonization and recurrent sinusitis ### Distinguishing Features Table | Feature | Atopic Polyps (Answer B) | Allergic Fungal Sinusitis (A) | EGPA (C) | Inverted Papilloma (D) | |---------|--------------------------|-------------------------------|----------|------------------------| | **Appearance** | Pale, smooth, glistening | Thick inspissated mucin | Polyps + systemic vasculitis | Unilateral, friable, bleeding | | **IgE Level** | Markedly elevated | Elevated (but with fungal sensitization) | Elevated | Normal | | **CT Imaging** | Bilateral homogeneous opacification | Heterogeneous with central hyperdensity | Bilateral with systemic features | Unilateral, bone erosion | | **Laterality** | Bilateral | Often unilateral/asymmetric | Bilateral | Typically unilateral | | **Key Distinguisher** | Lifelong atopy (asthma + eczema) | Fungal hyphae on culture/stain | Eosinophilia >1500/μL, vasculitis, neuropathy | Malignant potential | | **Fungal element** | Absent | Present (essential criterion) | Absent | Absent | ### Why NOT EGPA? EGPA (Churg-Strauss) presents with nasal polyps, asthma, and elevated IgE, but requires **systemic vasculitis features**: peripheral eosinophilia >1500/μL, pulmonary infiltrates, mononeuritis multiplex, cardiac involvement, or skin purpura. This patient has none of these systemic features — isolated nasal polyps with atopy do not meet EGPA diagnostic criteria (ACR/EULAR 2022). ### Why NOT Inverted Papilloma? Inverted papilloma is **unilateral**, arises from the lateral nasal wall, appears friable and bleeding (not pale/smooth), and is associated with HPV. It has malignant potential (~10% transformation to SCC). This patient's bilateral presentation excludes it. **High-Yield:** Bilateral pale smooth polyps + markedly elevated IgE + lifelong asthma + eczema = Atopic nasal polyposis. AFS requires fungal culture positivity and heterogeneous CT density — neither is present here. ### Management - **First-line**: Intranasal corticosteroids (mometasone, fluticasone) — reduce eosinophilic inflammation - **Adjuncts**: Antihistamines, leukotriene antagonists (montelukast — especially with concurrent asthma) - **Allergen avoidance** and immunotherapy if indicated - **FESS** — Reserved for medical failures or severe obstruction - **Biologics**: Omalizumab (anti-IgE) or dupilumab (anti-IL-4Rα) for refractory cases **Clinical Pearl:** Recurrent polyps after FESS suggest inadequate medical therapy; escalate to biologic agents before re-operation. Dupilumab is now FDA-approved for chronic rhinosinusitis with nasal polyposis (CRSwNP). [cite: Cummings Otolaryngology – Head and Neck Surgery, 7th ed., Chapter on Nasal Polyps and Chronic Rhinosinusitis; Meltzer EO et al. Rhinitis and sinusitis: relationship, pathophysiology, diagnosis and treatment. J Allergy Clin Immunol. 2004]